In vitro activity of lefamulin tested against Streptococcus pneumoniae with defined serotypes, including multidrug-resistant isolates causing lower respiratory tract infections in the United States

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 7, 2016, Pages 4407-4411

  Mendes, Rodrigo E ^a   Farrell, David J ^a   Flamm, Robert K ^a   Talbot, George H ^b   Ivezic Schoenfeld, Zrinka ^c   Paukner, Susanne ^c   Sader, Helio S ^a  

^a JMI LABORATORIES   (United States)

^b Talbot Advisors LLC   (United States)

^c Nabriva Therapeutics Inc   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTRIAXONE; CEPHALOSPORIN; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; FOLIC ACID; IMIPENEM; LEFAMULIN; LEVOFLOXACIN; LINEZOLID; PENICILLIN DERIVATIVE; PNEUMOCOCCUS POLYSACCHARIDE; PNEUMOCOCCUS VACCINE; TETRACYCLINE; VANCOMYCIN; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE;

ADULT; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; CLINICAL EVALUATION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LOWER RESPIRATORY TRACT INFECTION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; UNITED STATES; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; RESPIRATORY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ERYTHROMYCIN; MICROBIAL SENSITIVITY TESTS; RESPIRATORY TRACT INFECTIONS; SEROGROUP; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

EID: 84977080157     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00627-16     Document Type: Article

References (27)

1. Stratton CW. 2005. An overview of community-acquired respiratory tract infections. Adv Stud Pharm 2:212-218.
2. Prina E, Ranzani OT, Torres A. 2015. Community-acquired pneumonia. Lancet 386:1097-1108. http://dx.doi.org/10.1016/S0140-6736(15)60733-4.
3. Jain S, Williams DJ, Arnold SR, Ampofo K, Bramley AM, Reed C, Stockmann C, Anderson EJ, Grijalva CG, Self WH, Zhu Y, Patel A, Hymas W, Chappell JD, Kaufman RA, Kan JH, Dansie D, Lenny N, Hillyard DR, Haynes LM, Levine M, Lindstrom S, Winchell JM, Katz JM, Erdman D, Schneider E, Hicks LA, Wunderink RG, Edwards KM, Pavia AT, McCullers JA, Finelli L, CDC EPIC Study Team. 2015. Community-acquired pneumonia requiring hospitalization among U.S. children. N Engl J Med 372:835-845. http://dx.doi.org/10.1056/NEJMoa1405870.
4. File TM, Jr, Marrie TJ. 2010. Burden of community-acquired pneumonia in North American adults. Postgrad Med 122:130-141. http://dx.doi.org/10.3810/pgm.2010.03.2130.
5. Shang R, Wang J, Guo W, Liang J. 2013. Efficient antibacterial agents: a review of the synthesis, biological evaluation and mechanism of pleuromutilin derivatives. Curr Top Med Chem 13:3013-3025. http://dx.doi.org/10.2174/15680266113136660217.
6. Novak R. 2011. Are pleuromutilin antibiotics finally fit for human use? Ann N Y Acad Sci 1241:71-81. http://dx.doi.org/10.1111/j.1749-6632.2011.06219.x.
7. Eyal Z, Matzov D, Krupkin M, Wekselman I, Paukner S, Zimmerman E, Rozenberg H, Bashan A, Yonath A. 2015. Structural insights into species-specific features of the ribosome from the pathogen Staphylococcus aureus. Proc Natl Acad Sci USA 112:E5805-E5814. http://dx.doi.org/10.1073/pnas.1517952112.
8. Schlunzen F, Pyetan E, Fucini P, Yonath A, Harms JM. 2004. Inhibition of peptide bond formation by pleuromutilins: the structure of the 50S ribosomal subunit from Deinococcus radiodurans in complex with tiamulin. Mol Microbiol 54:1287-1294. http://dx.doi.org/10.1111/j.1365-2958.2004.04346.x.
9. Davidovich C, Bashan A, Auerbach-Nevo T, Yaggie RD, Gontarek RR, Yonath A. 2007. Induced-fit tightens pleuromutilins binding to ribosomes and remote interactions enable their selectivity. Proc Natl Acad Sci U S A 104:4291-4296. http://dx.doi.org/10.1073/pnas.0700041104.
10. Long KS, Hansen LH, Jakobsen L, Vester B. 2006. Interaction of pleuromutilin derivatives with the ribosomal peptidyl transferase center. Antimicrob Agents Chemother 50:1458-1462. http://dx.doi.org/10.1128/AAC.50.4.1458-1462.2006.
11. Rubino CM, Xue B, Bhavnani SM, Prince WT, Ivezic-Schoenfeld Z, Wicha WW, Ambrose PG. 2015. Population pharmacokinetic analyses for BC-3781 using phase 2 data from patients with acute bacterial skin and skin structure infections. Antimicrob Agents Chemother 59:282-288. http://dx.doi.org/10.1128/AAC.02033-13.
12. Prince WT, Ivezic-Schoenfeld Z, Lell C, Tack KJ, Novak R, Obermayr F, Talbot GH. 2013. Phase II clinical study of BC-3781, a pleuromutilin antibiotic, in treatment of patients with acute bacterial skin and skin structure infections. Antimicrob Agents Chemother 57:2087-2094. http://dx.doi.org/10.1128/AAC.02106-12.
13. Bhavnani SM, Ambrose PG, Wicha WW, Ivezic-Schoenfeld Z, Prince WT, Rubino CM. 2015. Pharmacokinetic-pharmacodynamic (PK-PD) target attainment (TA) analyses supporting lefamulin dose selection for the treatment of patients with community-acquired bacterial pneumonia (CABP), abstr 793. ID Week, San Diego, CA, 7 to 11 October 2015.
14. Sader HS, Biedenbach DJ, Paukner S, Ivezic-Schoenfeld Z, Jones RN. 2012. Antimicrobial activity of the investigational pleuromutilin compound BC-3781 tested against gram-positive organisms commonly associated with acute bacterial skin and skin structure infections. Antimicrob Agents Chemother 56:1619-1623. http://dx.doi.org/10.1128/AAC.05789-11.
15. Sader HS, Paukner S, Ivezic-Schoenfeld Z, Biedenbach DJ, Schmitz FJ, Jones RN. 2012. Antimicrobial activity of the novel pleuromutilin antibiotic BC-3781 against organisms responsible for community-acquired respiratory tract infections (CARTIs). J Antimicrob Chemother 67:1170-1175. http://dx.doi.org/10.1093/jac/dks001.
16. Paukner S, Sader HS, Ivezic-Schoenfeld Z, Jones RN. 2013. Antimicrobial activity of the pleuromutilin antibiotic BC-3781 against bacterial pathogens isolated in the SENTRY antimicrobial surveillance program in 2010. Antimicrob Agents Chemother 57:4489-4495. http://dx.doi.org/10.1128/AAC.00358-13.
17. Zeitlinger M, Schwameis R, Burian A, Burian B, Matzneller P, Muller M, Wicha WW, Strickmann DB, Prince W. 2016. Simultaneous assessment of the pharmacokinetics of a pleuromutilin, lefamulin, in plasma, soft tissues and pulmonary epithelial lining fluid. J Antimicrob Chemother 71:1022-1026. http://dx.doi.org/10.1093/jac/dkv442.
18. Mendes RE, Hollingsworth RC, Costello A, Jones RN, Isturiz RE, Hewlett D, Jr, Farrell DJ. 2015. Noninvasive Streptococcus pneumoniae serotypes recovered from hospitalized adult patients in the United States in 2009 to 2012. Antimicrob Agents Chemother 59:5595-5601. http://dx.doi.org/10.1128/AAC.00182-15.
19. Clinical and Laboratory Standards Institute. 2015. Performance standards for antimicrobial susceptibility testing; 25th informational supplement. CLSI M100-S25. Clinical and Laboratory Standards Institute, Wayne, PA.
20. Clinical and Laboratory Standards Institute. 2016. Performance standards for antimicrobial susceptibility testing; 26th informational supplement. CLSI M100-S26. Clinical and Laboratory Standards Institute, Wayne, PA.
21. EUCAST. 2016. Breakpoint tables for interpretation of MICs and zone diameters. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST-files/Breakpoint-tables/v-6.0-Breakpoint-table.pdf.
22. Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett NM, Petit S, Zansky SM, Harrison LH, Reingold A, Miller L, Scherzinger K, Thomas A, Farley MM, Zell ER, Taylor TH, Jr, Pondo T, Rodgers L, McGee L, Beall B, Jorgensen JH, Whitney CG. 2015. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis 15:301-309. http://dx.doi.org/10.1016/S1473-3099(14)71081-3.
23. Desai AP, Sharma D, Crispell EK, Baughman W, Thomas S, Tunali A, Sherwood L, Zmitrovich A, Jerris R, Satola SW, Beall B, Moore MR, Jain S, Farley MM. 2015. Decline in pneumococcal nasopharyngeal carriage of vaccine serotypes after the introduction of the 13-valent pneumococcal conjugate vaccine in children in Atlanta, Georgia. Pediatr Infect Dis J 34:1168-1174. http://dx.doi.org/10.1097/INF.0000000000000849.
24. Mendes RE, Biek D, Critchley IA, Farrell DJ, Sader HS, Jones RN. 2014. Decreased ceftriaxone susceptibility in emerging (35B and 6C) and persisting (19A) Streptococcus pneumoniae serotypes in the United States, 2011-2012: ceftaroline remains active in vitro among β-lactam agents. Antimicrob Agents Chemother 58:4923-4927. http://dx.doi.org/10.1128/AAC.02976-14.
25. Richter SS, Diekema DJ, Heilmann KP, Dohrn CL, Riahi F, Doern GV. 2014. Changes in pneumococcal serotypes and antimicrobial resistance after introduction of the 13-valent conjugate vaccine in the United States. Antimicrob Agents Chemother 58:6484-6489. http://dx.doi.org/10.1128/AAC.03344-14.
26. Richter SS, Heilmann KP, Dohrn CL, Riahi F, Diekema DJ, Doern GV. 2013. Pneumococcal serotypes before and after introduction of conjugate vaccines, United States, 1999-2011. Emerg Infect Dis 19:1074-1083. http://dx.doi.org/10.3201/eid1907.121830.
27. Link-Gelles R, Thomas A, Lynfield R, Petit S, Schaffner W, Harrison L, Farley MM, Aragon D, Nicols M, Kirley PD, Zansky S, Jorgensen J, Juni BA, Jackson D, Moore MR, Lipsitch M. 2013. Geographic and temporal trends in antimicrobial nonsusceptibility in Streptococcus pneumoniae in the post-vaccine era in the United States. J Infect Dis 208:1266-1273. http://dx.doi.org/10.1093/infdis/jit315.